CA
NZ
UK
AU
IND
US
Cardiff Oncology (NASDAQ:CRDF) shares are indicated up 2.23% at $0.89 in premarket after the company appointed Leila Alland, MD, as interim Chief Medical Officer. She succeeds Roger Sidhu, MD, who stepped down. The stock closed Tuesday up 8.80% at $0.88.
Cellectis (NASDAQ:CLLS) shares are indicated up 5.71% at $1.11 in premarket after the company presented expanded preclinical data for .HEAL-101, its in vivo base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress. The stock closed …
Dyne Therapeutics (NASDAQ:DYN) shares are indicated down 4.19% at $16.23 in premarket after Oppenheimer downgraded the stock to Perform from Outperform and cut its price target to $15 from $40. Uncertainty around vHOT is the main focus for investors, even though the stock jumped …
GE HealthCare (NASDAQ:GEHC) shares are indicated up 7.09% at $76.15 in premarket after third-quarter results topped expectations and the company raised its 2026 outlook. Adjusted EPS of $1.34, up 25.1%, beat the $1.20 consensus, and revenue of $5.5 billion, up 7.2% with organic growth …
INVO Fertility (NASDAQ:IVF) shares are indicated up 1.12% at $0.62 in premarket after the company announced a 1-for-4 reverse split of its issued and outstanding and authorized common stock, effective October 30. Shares will begin trading on a split-adjusted basis on the Nasdaq Capital …
Rapport Therapeutics (NASDAQ:RAPP) shares are indicated down 22.21% at $21.42 in premarket after the company priced underwritten offerings of its common stock and convertible notes. The common stock offering of about $200 million, including about $25 million of pre-funded warrants in lieu of shares, …
Universal Health Services (NYSE:UHS) shares are indicated down 5.12% at $168.25 in premarket after third-quarter results that were mixed. Revenue of $4.73 billion, up 5.3%, and adjusted EPS of $5.22 were roughly in line with consensus of $5.15 to $5.31, but adjusted EBITDA of …
Absci Corporation (NASDAQ: ABSI) shares were trading at USD 10.51 on October 27, 2026, up 11.16%, with a relative volume at time of 2.01. The clinical-stage biopharmaceutical company announced interim Phase 1 data from its HEADLINE trial in June 2026, completed a public offering …
Beta Bionics (NASDAQ: BBNX) shares were trading at USD 21.41 on October 27, 2026, up 4.39%, with a relative volume at time of 2.55. The medical device company received an FDA Warning Letter in January 2026, began enrolling adults with type 2 diabetes in …
BioCryst (NASDAQ: BCRX) shares were trading at USD 8.01 on October 27, 2026, up 1.59%, with a relative volume at time of 2.28. The biotechnology company completed its merger with Astria Therapeutics on January 23, 2026, entered a navenibart license agreement with an affiliate …
Please wait processing your request...